NSW – Examining the Health of our Healthcare
A record $11.9 billion investment in health infrastructure over the next four years is driving a significant transformation of the NSW health landscape. Major upgrades to hospitals, including a new $750 million Royal Prince Alfred (RPA) Hospital will aim to deliver first-class health care to the community, through state-of-the-art health facilities and patient services. But while infrastructure is important, the real benefits to patient outcomes are delivered through the innovation of products and services from collaborative research. Close partnerships between Industry, Researchers and Government require deliberate planning, and are an essential part of the framework for Australia’s economic and social success. NSW Minister for Health The Hon Brad Hazzard will deliver a keynote outlining major developments in NSW Health infrastructure and budget allocations. pastevent
NSW – Examining the Health of our Healthcare
| Please sign in or create an account to register for this event before 05:00 PM on Tuesday 20 September. If online registrations are closed, please email [email protected] with your Full Name, Job Title, Company Name, State and Email Address to confirm availability. |
Overview
The American Chamber of Commerce in Australia presents Examining the Health of our Healthcare
NSW – Examining the Health of our Healthcare
A record $11.9 billion investment in health infrastructure over the next four years is driving a significant transformation of the NSW health landscape.
Major upgrades to hospitals, including a new $750 million Royal Prince Alfred (RPA) Hospital will aim to deliver first-class health care to the community, through state-of-the-art health facilities and patient services.
But while infrastructure is important, the real benefits to patient outcomes are delivered through the innovation of products and services from collaborative research.
Close partnerships between Industry, Researchers and Government require deliberate planning, and are an essential part of the framework for Australia’s economic and social success.
NSW Minister for Health The Hon Brad Hazzard will deliver a keynote outlining major developments in NSW Health infrastructure and budget allocations.
Announcing our panelists:
Following the keynote, panel speakers Sue Martin, Managing Director - Johnson & Johnson Medical Devices ANZ, Ravin Nand, Managing Director ANZ, Cochlear and Erica Kneipp, Research Director for Human Health at CSIRO will discuss the critical role of investing in collaborative R&D to improving the technology which benefits patient outcomes.
|
Speakers
 |
The Hon Brad Hazzard MP
Minister for Health |
|
|
 |
Erica Kneipp
Research Director for Human Health, CSIRO |
|
|
 |
Sue Martin
Managing Director, Johnson & Johnson Medical Devices ANZ |
|
|
 |
Ravin Nand
General Manager, Cochlear |
|
|
| |
|
|
|
|
 National Partners
 .png) 
Event Series Partners
.jpg)   
Exhibitors
To view our exhibitor opportunity pack contact [email protected]
|
.png) Event Details
| Date |
Tuesday 27 September 2022 |
| Time |
11:45 pm - 2:00 pm |
| Location |
Four Seasons Hotel
199 George St
The Rocks - NSW 2000 |
|
 Pricing
Member Non-Member
Individual (1) $169 $219
Table (10) $1,690 $2,190 |
Speaker Biographies
Hon Minister Brad Hazzard MP, Minister for Health NSW
Brad Hazzard is a senior Cabinet Minister in the NSW Government and has been the Minister for Health since 2017.
He has overseen record investment in health infrastructure and services, which has resulted in a hospital building boom across the state and the funding of thousands of new frontline positions.
NSW has a robust and innovative medical research knowledge economy, which the NSW Government is committed to supporting and expanding.
Brad has previously served as Minister for Family and Community Services and Minister for Social Housing, Attorney General and Minister for Justice, Minister for Planning and Infrastructure, as well as Minister Assisting the Premier on Infrastructure NSW.
He was also Leader of the House (Legislative Assembly) in the O’Farrell Government.
Brad started his professional life as a science teacher at North Sydney Boys’ High School. He later studied law at the University of NSW and was admitted as a solicitor in 1977. He also holds a Master of Laws from the University of Sydney.
He entered Parliament in 1991 as the State Member for Wakehurst, on Sydney’s Northern Beaches.
Much of his political career in the New South Wales Parliament has been served on the front bench. Brad held 17 portfolios in opposition, while maintaining a strong local presence in his electorate.
Brad has been a member of the NSW Liberal Party since 1983; in that time he’s held a number of executive positions, including ‘Regional President’ and member of the ‘State Executive’.
Erica Kneipp, Research Director for Human Health, CSIRO
Erica Kneipp is the Research Director for the Human Health program with CSIRO, Australia’s National Science Agency.
Her portfolio encompasses infectious disease preparedness, innovative diagnostic solutions and nutritional science and services and clinical trials. Erica works with a talented team of scientists and strategic collaborators to deliver research impact that drives transformation in the prevention, detection and response to health and biosecurity threats.
Prior to joining CSIRO, Erica was with the Australian National University (2019-2021) as Head of Research Strategy for the College of Health and Medicine where she led a program to reposition capabilities, diversify income and establish innovation pipelines.
She spent a decade in the Commonwealth Health Department senior executive service (2009-2019) supporting a number of national portfolios and Ministers. During this time was instrumental in establishing the Medical Research Future Fund, which has effectively double Australia’s investment in health and medical research, and Biomedical Translation Fund, an equity co-investment venture capital program, and worked with state jurisdictions on clinical trial reform.
She is on the Board of Brandon BioCatalyst (formerly known as the Medical Research Commercialisation Fund), the largest life science investment fund in Australian and New Zealand, and the National Centre for Indigenous Genomics.
Sue Martin, General Manager, Johnson & Johnson Medical Devices ANZ
Sue’s career with Johnson & Johnson, the largest healthcare company in the world, spans 20 years and includes experience across multiple countries and functions, from marketing and sales to general management. Since January 2018, Sue has been managing director for Johnson & Johnson Medical (JJM) Australia and New Zealand. She is responsible for the company’s entire Medical Devices portfolio in ANZ, including orthopaedics, general and speciality surgery, cardiovascular, and reconstructive surgery products.
Sue is a member and co-chair of the Johnson & Johnson Family of Companies Board in Australia and New Zealand and represents Australia and New Zealand on the Medical Devices Asia-Pacific Leadership Board. Sue has been a board member of the Medical Technology Association of Australia (MTAA) since 2018 and Vice-Chair since 2019. She lives in Melbourne with her husband and three boys.
Ravin Nand, Managing Director, Cochlear
Ravin Nand has over 17 years’ experience at the medical devices company Cochlear Limited – the world’s global leader in implantable hearing technology. With considerable time spent across the Asia Pacific region, including in South East Asia and India, Ravin holds deep knowledge and experience of the hearing health sector, technology and services.
Leveraging lessons learnt over a diverse career in health, banking and airlines, Ravin now leads Cochlear’s Australia and New Zealand operations as its General Manager, where he drives his team to develop programmes to increase awareness and create greater access for Australians suffering from hearing loss to improve quality of life outcomes. Ravin Nand is a Fellow of CPA, Australia and holds a Bachelor of Arts.
Ravin will share today perspectives on global trends in hearing healthcare and how it shapes future models of care & innovation.
|
 Invitation Transferable
Feel free to forward this invitation to anyone within your organisation or networks who you think might be interested in this event.
COVID PRECAUTIONS: The safety and wellbeing of our guests and colleagues is our utmost priority. AmCham will work with the venue to ensure hygiene procedures and government guidelines are followed with social distancing measures in place, visible sanitiser stations and Covid-19 marshals. We respectfully ask you do not attend on the day if you are experiencing any flu like symptoms.
UPDATE to Terms & Conditions
If Government Health Orders change and in-person events are suspended, the AmCham program will go virtual and links will be sent to all attendees. A 50% refund will be paid to ticket holders. (Please see Terms and Conditions for specific details).
AmCham Privacy Policy
AmCham Australia is committed to data privacy and protecting your personal information. By registering for this event, you agree that AmCham and its event partners may send you relevant information. (Please refer to our Privacy Policy for full details).. |